Literature DB >> 18717037

[Cytokine assessment in untreated hepatitis C virus infected patients and during interferon alpha +ribavirine therapy].

Małgorzata Inglot1, Andrzej Gładysz, Weronika Rymer, Irena Molin, Małgorzata Zalewska, Anna Machaj.   

Abstract

UNLABELLED: Many articles concerning the hepatitis C virus (HCV) infection emphasize the role of cytokines Th1- and Th2-dependent. The aim of our study was to assess the changes in the concentration of cytokines (IL-2, IFN-gamma, IL-4, IL-10) determined by ELISA test in serum of HCV infected patients treated with interferon alpha (IFN-alpha) and ribavirine.
RESULTS: The cytokine levels in HCV patients (n = 40) were similar to levels observed in healthy volunteers (p > 0.05). During IFN-alpha and ribavirine therapy no statistically significant changes in cytokine levels were observed in patients who achieved sustained virological response (SVR) compared to unsuccessfully treated patients (p > 0.05).
CONCLUSIONS: 1. Serum is not useful compartment to determinate level of cytokines by ELISA method in chronic hepatitis C. 2. The measurement of cytokine levels using ELISA test was not confirmed to be useful in monitoring and assessment of the therapy results in HCV infected patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18717037

Source DB:  PubMed          Journal:  Wiad Lek        ISSN: 0043-5147


  2 in total

1.  Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis.

Authors:  Cosimo Marcello Bruno; Maria Valenti; Gaetano Bertino; Annalisa Ardiri; Alfredo Amoroso; Maria Consolo; Clorinda Maria Mazzarino; Sergio Neri
Journal:  Ann Saudi Med       Date:  2011 Jul-Aug       Impact factor: 1.526

2.  Serum profile of T helper 1 and T helper 2 cytokines in hepatitis C virus infected patients.

Authors:  Masoomeh Sofian; Arezoo Aghakhani; Ali Asghar Farazi; Mohammad Banifazl; Ali Eslamifar; Niloofar Rashidi; Akbar Khadem Sadegh; Amitis Ramezani
Journal:  Hepat Mon       Date:  2012-12-29       Impact factor: 0.660

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.